Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652573 · ClinicalTrials.gov registry record · NA
Calcitonin for Treating X-linked Hypophosphatemia
A NA study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01652573: Completed NA study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Yale University.
NCT01652573 is a NA study of Hypophosphatemic Rickets, X-Linked Dominant that has completed, run by Yale University. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01652573, a NA study of Hypophosphatemic Rickets, X-Linked Dominant, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will: 1. Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH. 2. Evaluate whether nasal calcitonin improves serum phosphate levels in XLH. 3. Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine. 4. Make sure that nasal calcitonin is safe and well tolerated.
Primary Outcome
FGF23 will be measured 0 to 24 hours post dose during a 24 hour admission and AUC calculated.
Conditions Studied
Interventions
- DRUG nasal salmon calcitonin
- DRUG Saline Nasal Spray Placebo
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT01652573 record still lists
NCT01652573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypophosphatemic Rickets, X-Linked Dominant appearing as the primary indexed condition, and to 2 interventions - of which nasal salmon calcitonin is the first listed.
NCT01652573 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01652573 about?
NCT01652573 is a clinical study titled "Calcitonin for Treating X-linked Hypophosphatemia". X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already...
What is the current status of trial NCT01652573?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-03. Estimated completion is 2015-09.
What conditions does trial NCT01652573 study?
This clinical trial studies the following conditions: Hypophosphatemic Rickets, X-Linked Dominant.
What interventions are being tested in trial NCT01652573?
The interventions under investigation include: nasal salmon calcitonin (DRUG), Saline Nasal Spray Placebo (DRUG).
Who is sponsoring clinical trial NCT01652573?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652573 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatemic Rickets, X-Linked Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01652573's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia